ArticleJournal of clinical microbiology2011
Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid.
Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 90 citations in OpenAlex.
- PCR-Confirmed Convexity Subarachnoid Neurocysticercosis with Negative Serology: A Case Report.Pathogens (Basel, Switzerland) · 2026Article
- Role of Advanced Multimodality Synthetic MRI and Dynamic Contrast-Enhanced MRI Derived Parameters in the Differentiating Neurocysticercosis and Tuberculomas.Clinical neuroradiology · 2026Article
- Molecular diagnostics in cerebrospinal fluid for the diagnosis of central nervous system infections.Clinical microbiology reviews · 2024Review
- The performance of a point-of-care test for the diagnosis of Neurocysticercosis in a resource-poor community setting in Zambia - a diagnostic accuracy study.EClinicalMedicine · 2024Article
- Evaluating the modulation of peripheral immune profile in people living with HIV and (Neuro)cysticercosis.PLoS neglected tropical diseases · 2024Article
- From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis.Frontiers in parasitology · 2024Review
- Neurocysticercosis Diagnosis in a Non-Endemic Country: France.Pathogens (Basel, Switzerland) · 2023Article
- Serological and molecular detection of neurocysticercosis among epileptic patients in Nagpur, Maharashtra state (India).Helminthologia · 2023Article
- Collaborative Studies for the Detection ofMicroorganisms · 2021Article
- Subarachnoid neurocysticercosis: emerging concepts and treatment.Current opinion in infectious diseases · 2020Review
- Taenia solium Cysticercosis and Its Impact in Neurological Disease.Clinical microbiology reviews · 2020Review
- Recent advances in nucleic acid-based methods for detection of helminth infections and the perspective of biosensors for future development.Parasitology · 2020Review
- Immunodiagnosis of human neurocysticercosis: comparative performance of serum diagnostic tests in Mexico.Parasitology research · 2019Article
- Comparison of complementary diagnostic tests in cerebrospinal fluid and serum for neurocysticercosis.Heliyon · 2018Article
- Pediatric neurocysticercosis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018Review
- Low sensitivity and frequent cross-reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis.Tropical medicine & international health : TM & IH · 2018Article
- Next-Generation Sequencing of Cerebrospinal Fluid for the Diagnosis of Neurocysticercosis.Frontiers in neurology · 2018Article
- Present status of laboratory diagnosis of human taeniosis/cysticercosis in Europe.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Review
- Validity of a PCR assay in CSF for the diagnosis of neurocysticercosis.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Treatment of racemose neurocysticercosis.Surgical neurology international · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurocysticercosis (NC), caused by the larval stage of Taenia solium, is one of the most common parasitic diseases of the central nervous system. The diagnosis of NC is mostly based on costly brain neuroimaging (computed tomography and/or nuclear magnetic resonance), which is rarely accessible in most affected areas. The most sensitive and specific tools for NC diagnosis are imagery techniques. The identification of specific antibodies and antigens is currently used only to support NC diagnosis due to their limited specificity and sensitivity. This study was performed to compare immunodiagnostic assays (antibody detection by enzyme-linked immunosorbent assay [ELISA] and enzyme-linked immunoelectrotransfer blotting [EITB] and HP10 antigen detection by ELISA) with the detection of parasite DNA by PCR amplification of a repetitive element of the parasite genome in the cerebrospinal fluid (CSF) of 121 radiologically and clinically characterized NC patients. Patients were divided into six groups according to the stage of the parasites and their localization. The CSF cellularity of each patient was also recorded. When all patients were considered, PCR exhibited the highest sensitivity (95.9%) and variable specificity (80% or 100%) depending on the controls used. The sensitivities of antibody detection by ELISA and EITB were not significantly different, and ELISA identified HP10 antigen mostly when vesicular cysticerci were located in the subarachnoideal basal cisterns. These results can help in the selection of different individual assays or combinations of assays to be used in NC diagnosis according to different requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.